Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Superficial bladder cancer therapy.

Emmanuel Schenkman1, Donald L Lamm

  • 1West Virginaia University, Morgantown, WV, USA.

Thescientificworldjournal
|September 7, 2004
PubMed
Summary

Bacillus Calmette-Guerin (BCG) immunotherapy is the most effective treatment for superficial bladder cancer (TCC), reducing recurrence, progression, and mortality. Other therapies like intravesical chemotherapy show limited benefits, while new treatments are under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

European urology·2024
Same author

Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter.

Bladder cancer (Amsterdam, Netherlands)·2024
Same author

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Nature medicine·2024
Same author

Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Nature medicine·2024
Same author

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Nature medicine·2024
Same author

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.

European urology·2023

Area of Science:

  • Uro-oncology
  • Cancer immunotherapy
  • Superficial bladder cancer management

Background:

  • Superficial transitional cell carcinoma (TCC) of the bladder presents treatment challenges despite advances.
  • Intravesical therapy aims to treat, prevent recurrence, and progression, and prolong survival for Ta, T1, and carcinoma in situ (CIS) stages.
  • Tumor stage and grade are primary determinants of survival outcomes.

Purpose of the Study:

  • To review and summarize recent advancements in the therapy of superficial TCC.
  • To evaluate the efficacy of various intravesical treatments for bladder cancer.
  • To highlight the role of immunotherapy and chemotherapy in managing superficial bladder cancer.

Main Methods:

  • Review of current literature on intravesical therapies for superficial bladder cancer.
  • Analysis of treatment outcomes for Bacillus Calmette-Guerin (BCG) immunotherapy and intravesical chemotherapy.
  • Summary of ongoing investigations into novel therapeutic agents and modalities.

Main Results:

  • Intravesical chemotherapy offers modest reductions in short-term (20%) and long-term (7%) recurrence but does not impact progression or mortality.
  • Bacillus Calmette-Guerin (BCG) immunotherapy is the most effective treatment and prophylaxis for TCC (Ta, T1, CIS), reducing recurrence, progression, and mortality.
  • Emerging therapies including interferons, Keyhole-limpet hemocyanin (KLH), bropirimine, and Photofrin-Photodynamic Therapy (PDT) show promising early results.

Conclusions:

  • BCG immunotherapy remains the gold standard for superficial TCC, offering significant benefits in disease control and survival.
  • While chemotherapy has a role in recurrence reduction, its impact on progression and mortality is limited.
  • Further research into novel agents and therapies is crucial for improving outcomes in superficial bladder cancer treatment.

Related Experiment Videos